Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non –ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial

Conclusions Doubling the ticagrelor LD achieved faster onset and greater platelet inhibition without an increase in adverse events in patients with NSTE-ACS undergoing PCI.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research